ループス治療薬市場-世界の産業規模、シェア、動向、機会、予測、2018～2028年、治療タイプ別、投与経路別、エンドユーザー別、地域別、競合

世界のループス治療薬市場は、予測期間2024～2028年に手ごわい成長を示すと予測されています。

世界の狼瘡治療薬市場の主要促進要因の一つは、この疾患の有病率の増加です。自己免疫疾患であるループスは、身体の免疫システムが自身の組織や臓器を攻撃することで発症します。ループスに関連した炎症は、関節、皮膚、腎臓、血液細胞、脳、心臓、肺など、さまざまな身体機能に影響を及ぼす可能性があります。狼瘡の徴候や症状は他の病気とよく似ているため、診断が難しいこともあります。すべての症例ではありませんが、多くの場合、狼瘡の症状で最もよく知られているのは、両頬に蝶の羽を広げたような顔面の発疹です。生まれつきループスの素因を持っている人もいれば、病気や薬、あるいは日光によって発症することもあります。アメリカ狼瘡財団によると、世界中で少なくとも500万人が狼瘡に罹患しており、この病気は15歳から44歳の年齢層に多く見られるといわれています。

ループスの有病率の増加がループス治療薬市場の成長を促進

ループス治療薬市場は、世界のループス患者の増加により拡大が見込まれています。ループスの有病率が上昇している理由はまだ完全には解明されていないが、調査によっていくつかの潜在的要因が特定されています。米国ループス財団によると、ループスに罹患している成人の10人中9人は女性です。重要な要因の一つは遺伝です。特定の遺伝的変異がループスの発症リスクを高めることが研究で示されています。例えば、IRF5と呼ばれる遺伝子に特定の変異を持つ人はループスを発症しやすいです。しかし、遺伝だけではループスの有病率の増加を説明することはできないです。環境要因も重要な役割を果たしています。公害、毒素、感染症などの環境要因がループスの発症に関係しています。シリカのような特定の化学物質や汚染物質への曝露は、狼瘡の発症リスクを高めることが示されており、世界狼瘡治療薬市場の拡大につながっています。さらに、エプスタイン・バーウイルスやサイトメガロウイルスなどの感染症もループスの発症に関連しています。ライフスタイルや食生活の変化も、ループス有病率の上昇に寄与している可能性があります。研究論文"Global epidemiology of systemic lupus erythematosus：a comprehensive systematic analysis and modelling study"によると、全身性エリテマトーデス（SLE）は最も一般的なループスです。一般人口におけるSLEの発症率は、中央アジアの10万人年当たり1.18（0.16～3.68）から中央欧州の10万人年当たり13.74（3.2～31.82）まで幅があります。SLE発症率の高い上位4カ国はポーランドで、米国、バルバドス、中国が続いた。加工食品が多く栄養価の低い食事は体内の炎症を増加させ、狼瘡のような自己免疫疾患の引き金となります。さらに、座りがちな生活や肥満は、狼瘡の発症リスクの増加と関連しており、世界の狼瘡治療薬市場の拡大が期待されています。世界心臓連盟によると、2025年までに27億人の成人が過体重または肥満になる可能性があります。

創薬研究開発の活発化が世界のループス治療薬市場を牽引

ループスは、皮膚、関節、腎臓、肺など身体の様々な部分に影響を及ぼす複雑な疾患です。ループスの症状を抑える治療法はあるが、治療法はないです。そのため、患者の転帰と生活の質を改善し、世界のループス治療薬市場の成長につなげるためには、ループス治療薬の研究開発（R&D）を強化することが重要です。狼瘡の新規治療薬開発における主な課題の一つは、この疾患の複雑な性質です。狼瘡は多因子疾患であり、その発症と進行には多くの要因が関与しています。これらの要因には、遺伝的要因、環境要因、ホルモン要因が含まれます。このような課題にもかかわらず、近年、ループスの新しい治療薬の開発に対する関心が高まっています。その理由の一つは、この疾患の根本的なメカニズムに対する理解が深まってきたことです。遺伝子研究と技術の進歩により、研究者はループスの発症と進行に関与する特定の遺伝子と経路を特定することができるようになっています。この知識は、これらの特定の遺伝子や経路を標的とする新薬の開発につながっています。ループス治療薬への関心が高まっているもう一つの理由は、新しい治療法に対する需要の高まりです。現在、狼瘡の治療薬はあるが、すべての患者に有効とは限らず、副作用が大きいものも多いです。そのため、副作用を最小限に抑えながら、ループスの症状を効果的に管理することができる、新しく改良された治療法が必要とされており、それが世界のループス治療薬市場の成長を増大させています。研究者と産業界の協力は、基礎研究と臨床開発のギャップを埋め、新しい治療薬の開発を加速させるのに役立ちます。研究者が協力することで、産業界の専門知識やリソースを活用して新薬や治療法を開発することができ、ループス治療薬の世界の大きな需要につながっています。資金提供や共同研究だけでなく、ループス治療薬の研究開発努力を高めるために活用されている技術的進歩もあります。例えば、人工知能や機械学習の進歩は、新たな創薬対象の同定や創薬プロセスの加速に役立っています。同様に、遺伝子編集や遺伝子治療の進歩は、狼瘡に対するより的を絞った個別化治療の開発に役立っており、これは世界の狼瘡治療薬市場の成長を促進すると期待されています。2023年5月9日現在、clinicaltrials.govによると、ループス治療薬に関連するさまざまな開発段階にある研究は世界で約278件あります。

合併、買収、提携

2021年6月、プロジェンテック社はグラクソ・スミスクライン社と、新しい全身性エリテマトーデス（SLEまたはループス）の測定・管理ツールの研究に関して18ヶ月の契約を締結しました。

2023年1月、EVOQセラピューティクスは、ギリアド・サイエンシズとの共同研究およびライセンシング契約を開始し、ギリアド・サイエンシズの技術を発展させ、ループス治療のための免疫療法を創出します。同契約に基づき、両社はRAおよびループスに対する免疫療法の前臨床開発を共同で進める。

調査範囲

本レポートでは、世界のループス治療薬市場を、以下に詳述する業界動向に加えて、以下のカテゴリーに分類しています：

ループス治療薬市場：治療タイプ別

• 非ステロイド性抗炎症薬
• 副腎皮質ステロイド薬
• 抗マラリア薬
• 免疫抑制剤
• 生物製剤
• その他

ループス治療薬市場：投与経路別

• 経口
• 静脈内
• 皮下

ループス治療薬市場：エンドユーザー別

• 病院・クリニック
• 外来
• その他

ループス治療薬市場：地域別

• 欧州
• フランス
• ドイツ
• 英国
• イタリア
• スペイン
• アジア太平洋
• 中国
• インド
• 日本
• オーストラリア
• 韓国
• 北米
• 米国
• カナダ
• メキシコ
• 中東・アフリカ
• サウジアラビア
• アラブ首長国連邦
• 南アフリカ
• トルコ

競合情勢

• 企業プロファイル：世界のループス治療薬市場における主要企業の詳細分析

利用可能なカスタマイズ：

• TechSci Research社は、与えられた市場データをもとに、企業固有のニーズに応じたカスタマイズを提供しています。レポートでは以下のカスタマイズが可能です。

企業情報

• 追加市場企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 COVID-19が世界のループス治療薬市場に与える影響

第6章 臨床試験分析

第7章 臨床試験分析世界のループス治療薬市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 治療薬タイプ別（非ステロイド性抗炎症薬、副腎皮質ステロイド薬、抗マラリア薬、免疫抑制薬、生物製剤、その他）
  • 投与経路別（経口、静脈内、皮下）
  • エンドユーザー別（病院・クリニック、外来、その他）
  • 地域別
  • 企業別（2022年）
• 市場マップ
  • 治療タイプ別
  • 投与経路別
  • エンドユーザー別
  • 地域別

第8章 北米のループス治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療タイプ別
  • 投与経路別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第9章 欧州のループス治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療タイプ別
  • 投与経路別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • ドイツ
  • フランス
  • 英国
  • スペイン
  • イタリア

第10章 アジア太平洋のループス治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療タイプ別
  • 投与経路別
  • エンドユーザー別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第11章 南米のループス治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療タイプ別
  • 投与経路別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第12章 中東・アフリカのループス治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療タイプ別
  • 投与経路別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • トルコ

第13章 市場力学

• 促進要因
• 課題

第14章 市場動向と発展

• 製品上市
• 合併と買収

第15章 世界のループス治療薬市場のSWOT分析

第16章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第17章 競合情勢

• GlaxoSmithKline, plc.
• Novartis AG
• AstraZeneca, plc.
• F. Hoffmann-La Roche AG
• Eli Lilly and Company
• ImmuPharma PLC
• Pfizer, Inc.
• Sanofi S.A.
• Bristl Myers Squibb Company
• Merck & Co., Inc.

第18章 戦略的提言

第19章 調査会社について・免責事項

Global Lupus Therapeutics Market is anticipated to witness formidable growth in the forecast period, 2024-2028. One of the key drivers of the global lupus therapeutics market is the increasing prevalence of the disease. The autoimmune disease lupus is brought on when the body's immune system attacks its own tissues and organs. Lupus-related inflammation can impact a variety of bodily functions, including joints, skin, kidneys, blood cells, brain, heart, and lungs. Because of how frequently its signs and symptoms resemble those of other illnesses, lupus can be challenging to diagnose. In many but not all cases of lupus, the most recognizable lupus symptom is a facial rash that looks like butterfly wings unfolding across both cheeks. Some people are predisposed to lupus from birth, which can be brought on by illnesses, medications, or even sunlight. According to Lupus Foundation of America, at least five million people worldwide have a form of lupus and the disease is more prevalent among the people belonging to age group 15-44.

Lupus has no known cure, but treatments can help manage symptoms. The market for lupus therapeutics is also being driven by advancements in technology and the development of new drugs. There are currently only a few FDA-approved drugs for the treatment of lupus, but there are many promising drugs in the pipeline, propelling the growth of Global Lupus Therapeutics Market. In addition to traditional pharmaceuticals, there are also emerging therapies for lupus, such as gene therapy and stem cell therapy. These therapies have the potential to provide long-term relief from lupus symptoms and could be a game-changer in the treatment of the disease, leading to the expansion of Global Lupus Therapeutics Market. Apart from these, favorable government policies for developing Lupus Therapeutics and technological advancement for new applications propel the Global Lupus Therapeutics Market in the forecasted period. While there is currently no cure for lupus, several therapies are available to manage symptoms and prevent complications. The choice of therapy depends on the patient's symptoms, medical history, and other factors which are expected to grow Global Lupus Therapeutics Market.

Increasing Prevalence of Lupus propels the market growth for Lupus Therapeutics

The market for Lupus Therapeutics is anticipated to grow due to the rising cases of Lupus worldwide. The reasons behind the rising prevalence of lupus are not yet fully understood, but research has identified several potential factors. According to Lupus Foundation of America, 9 out of 10 adults who are suffering from lupus are women. One of the key factors is genetics. Studies have shown that certain genetic variations can increase the risk of developing lupus. For example, people with a specific variation in the gene known as IRF5 are more likely to develop lupus. However, genetics alone cannot explain the increasing prevalence of lupus. Environmental factors also play a significant role. Environmental factors such as pollution, toxins, and infectious agents have been linked to the development of lupus. Exposure to certain chemicals and pollutants, such as silica, has been shown to increase the risk of developing lupus, leading to the expansion of Global Lupus Therapeutics Market. Additionally, infections such as Epstein-Barr virus and cytomegalovirus have been linked to the onset of lupus. Changes in lifestyle and diet may also be contributing to the rising prevalence of lupus. According to a research article, "Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study", Systemic lupus erythematosus (SLE), is the most common type of lupus. The incidence of SLE in the general population varied from 1.18 (0.16 to 3.68) per 100 000 person-years in central Asia to 13.74 (3.2 to 31.82) per 100 000 person-years in central Europe. The top four countries with the highest estimates of SLE incidence were Poland followed by United States, Barbados, and China. A diet high in processed foods and low in nutrients can increase inflammation in the body, which can trigger autoimmune diseases such as lupus. Additionally, sedentary lifestyles and obesity have been linked to an increased risk of developing lupus, which is expected to expand Global Lupus Therapeutics Market. According to the World Heart Federation, by 2025, 2.7 billion adults might be overweight or obese.

Rising Research and Development in Drug Discovery drives Global Lupus Therapeutics Market

Lupus is a complex disease that can affect various parts of the body, such as the skin, joints, kidneys, and lungs. While there are treatments available to manage the symptoms of lupus, there is no cure. Therefore, increasing research and development (R&D) efforts for lupus therapeutics is crucial to improve patient outcomes and quality of life and leading to the growth of Global Lupus Therapeutics Market. One of the main challenges in developing new therapeutics for lupus is the complex nature of the disease. Lupus is a multifactorial disease, meaning that there are many factors that contribute to its development and progression. These factors include genetic, environmental, and hormonal factors. Despite the challenges, there has been a growing interest in developing new therapeutics for lupus in recent years. One reason for this is the increasing understanding of the underlying mechanisms of the disease. Advances in genetic research and technology have allowed researchers to identify specific genes and pathways that are involved in the development and progression of lupus. This knowledge has led to the development of new drugs that can target these specific genes and pathways. Another reason for the increasing interest in lupus therapeutics is the growing demand for new treatments. While there are currently treatments available for lupus, they are not always effective for all patients, and many have significant side effects. Therefore, there is a need for new and improved therapies that can effectively manage the symptoms of lupus while minimizing side effects, hence augmenting the growth of Global Lupus Therapeutics Market. Collaboration between researchers and industry helps bridge the gap between basic research and clinical development and accelerate the development of new therapeutics. By working together, researchers leverage the expertise and resources of industry to develop new drugs and therapies leading to the huge demand for lupus therapeutics globally. In addition to funding and collaboration, there are also technological advancements that are leveraged to increase R&D efforts for lupus therapeutics. For example, advances in artificial intelligence and machine learning help to identify new drug targets and accelerate the drug discovery process. Similarly, advances in gene editing and gene therapy have helped in the development of more targeted and personalized therapies for lupus, which is expected to propel the growth of Global Lupus Therapeutics Market. As of 9th May 2023, as per clinicaltrials.gov, there are around 278 studies in different phases of development related to Lupus Therapeutics worldwide.

Mergers, Acquisitions and Collaborations

In June 2021, Progentec collaborated with GlaxoSmithKline, plc for an 18-month agreement to research new systemic lupus erythematosus (SLE or lupus) measurement and management tools.

In January 2023, EVOQ Therapeutics launched its collaboration and licensing agreement with Gilead Sciences to advance the latter's technology and create immunotherapies for the treatment of lupus. In accordance with the terms of the agreement, the two businesses will collaborate to advance the preclinical development of immunotherapies for RA and lupus.

Market Segmentation

Global Lupus Therapeutics Market is segmented based on Treatment Type, Route of Administration and End-User. Based on Treatment Type, the global lupus therapeutics market is divided into NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, Biologics and Others. Based on Route of Administration, the global lupus therapeutics market is divided into Oral, Intravenous and Subcutaneous. Based on End-User, the global lupus therapeutics market is divided into Hospitals & Clinics, Ambulatory Care Centers and Others.

Market players

GlaxoSmithKline, plc., Novartis AG, AstraZeneca, plc., Hoffmann-La Roche AG, Eli Lilly and Company. ImmuPharma PLC, Pfizer, Inc., Sanofi S.A., Bristl Myers Squibb Company, Merck & Co., Inc. are the key players operating in the global lupus therapeutics market.

Report Scope:

In this report, Global Lupus Therapeutics Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Lupus Therapeutics Market, By Treatment Type:

• NSAIDs
• Corticosteroids
• Antimalarials
• Immunosuppressants
• Biologics
• Others

Lupus Therapeutics Market, By Route of Administration:

• Oral
• Intravenous
• Subcutaneous

Lupus Therapeutics Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Lupus Therapeutics Market, By region:

• Europe
• France
• Germany
• United Kingdom
• Italy
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• North America
• United States
• Canada
• Mexico
• Middle East and Africa
• Saudi Arabia
• UAE
• South Africa
• Turkey

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in Global Lupus Therapeutics Market.

Available Customizations:

• With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Impact of COVID-19 on Global Lupus Therapeutics Market

6. Clinical Trial Analysis

• 6.1. Ongoing Clinical Trials
• 6.2. Completed Clinical Trials
• 6.3. Terminated Clinical Trials
• 6.4. Breakdown of Pipeline, By Development Phase
• 6.5. Breakdown of Pipeline, By Status
• 6.6. Breakdown of Pipeline, By Study Type
• 6.7. Breakdown of Pipeline, By Region
• 6.8. Clinical Trials Heat Map

7. Global Lupus Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type (NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, Biologics, Others)
  • 7.2.2. By Route of Administration (Oral, Intravenous, Subcutaneous)
  • 7.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 7.2.4. By Region
  • 7.2.5. By Company (2022)
• 7.3. Market Map
  • 7.3.1. By Treatment Type
  • 7.3.2. By Route of Administration
  • 7.3.3. By End User
  • 7.3.4. By Region

8. North America Lupus Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Lupus Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By End User
  • 8.3.2. Canada Lupus Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By End User
  • 8.3.3. Mexico Lupus Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By End User

9. Europe Lupus Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Europe: Country Analysis
  • 9.3.1. Germany Lupus Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By End User
  • 9.3.2. France Lupus Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By End User
  • 9.3.3. United Kingdom Lupus Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By End User
  • 9.3.4. Spain Lupus Therapeutics Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Treatment Type
      • 9.3.4.2.2. By Route of Administration
      • 9.3.4.2.3. By End User
  • 9.3.5. Italy Lupus Therapeutics Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Treatment Type
      • 9.3.5.2.2. By Route of Administration
      • 9.3.5.2.3. By End User

10. Asia-Pacific Lupus Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. Asia-Pacific: Country Analysis
  • 10.3.1. China Lupus Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By End User
  • 10.3.2. India Lupus Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By End User
  • 10.3.3. Japan Lupus Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By End User
  • 10.3.4. South Korea Lupus Therapeutics Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Treatment Type
      • 10.3.4.2.2. By Route of Administration
      • 10.3.4.2.3. By End User
  • 10.3.5. Australia Lupus Therapeutics Market Outlook
    • 10.3.5.1. Market Size & Forecast
      • 10.3.5.1.1. By Value
    • 10.3.5.2. Market Share & Forecast
      • 10.3.5.2.1. By Treatment Type
      • 10.3.5.2.2. By Route of Administration
      • 10.3.5.2.3. By End User

11. South America Lupus Therapeutics Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Treatment Type
  • 11.2.2. By Route of Administration
  • 11.2.3. By End User
  • 11.2.4. By Country
• 11.3. South America: Country Analysis
  • 11.3.1. Brazil Lupus Therapeutics Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Treatment Type
      • 11.3.1.2.2. By Route of Administration
      • 11.3.1.2.3. By End User
  • 11.3.2. Argentina Lupus Therapeutics Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Treatment Type
      • 11.3.2.2.2. By Route of Administration
      • 11.3.2.2.3. By End User
  • 11.3.3. Colombia Lupus Therapeutics Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Treatment Type
      • 11.3.3.2.2. By Route of Administration
      • 11.3.3.2.3. By End User

12. Middle East and Africa Lupus Therapeutics Market Outlook

• 12.1. Market Size & Forecast
  • 12.1.1. By Value
• 12.2. Market Share & Forecast
  • 12.2.1. By Treatment Type
  • 12.2.2. By Route of Administration
  • 12.2.3. By End User
  • 12.2.4. By Country
• 12.3. MEA: Country Analysis
  • 12.3.1. South Africa Lupus Therapeutics Market Outlook
    • 12.3.1.1. Market Size & Forecast
      • 12.3.1.1.1. By Value
    • 12.3.1.2. Market Share & Forecast
      • 12.3.1.2.1. By Treatment Type
      • 12.3.1.2.2. By Route of Administration
      • 12.3.1.2.3. By End User
  • 12.3.2. Saudi Arabia Lupus Therapeutics Market Outlook
    • 12.3.2.1. Market Size & Forecast
      • 12.3.2.1.1. By Value
    • 12.3.2.2. Market Share & Forecast
      • 12.3.2.2.1. By Treatment Type
      • 12.3.2.2.2. By Route of Administration
      • 12.3.2.2.3. By End User
  • 12.3.3. UAE Lupus Therapeutics Market Outlook
    • 12.3.3.1. Market Size & Forecast
      • 12.3.3.1.1. By Value
    • 12.3.3.2. Market Share & Forecast
      • 12.3.3.2.1. By Treatment Type
      • 12.3.3.2.2. By Route of Administration
      • 12.3.3.2.3. By End User
  • 12.3.4. Turkey Lupus Therapeutics Market Outlook
    • 12.3.4.1. Market Size & Forecast
      • 12.3.4.1.1. By Value
    • 12.3.4.2. Market Share & Forecast
      • 12.3.4.2.1. By Treatment Type
      • 12.3.4.2.2. By Route of Administration
      • 12.3.4.2.3. By End User

13. Market Dynamics

• 13.1. Drivers
• 13.2. Challenges

14. Market Trends & Developments

• 14.1. Product Launches
• 14.2. Mergers & Acquisitions
• 14.3. Recent Developments

15. Global Lupus Therapeutics Market: SWOT Analysis

16. Porter's Five Forces Analysis

• 16.1. Competition in the Industry
• 16.2. Potential of New Entrants
• 16.3. Power of Suppliers
• 16.4. Power of Customers
• 16.5. Threat of Substitute Products

17. Competitive Landscape

• 17.1. Business Overview
• 17.2. Company Snapshot
• 17.3. Products & Services
• 17.4. Financials (In case of listed companies)
• 17.5. Recent Developments
• 17.6. SWOT Analysis
  • 17.6.1. GlaxoSmithKline, plc.
  • 17.6.2. Novartis AG
  • 17.6.3. AstraZeneca, plc.
  • 17.6.4. F. Hoffmann-La Roche AG
  • 17.6.5. Eli Lilly and Company
  • 17.6.6. ImmuPharma PLC
  • 17.6.7. Pfizer, Inc.
  • 17.6.8. Sanofi S.A.
  • 17.6.9. Bristl Myers Squibb Company
  • 17.6.10. Merck & Co., Inc.

18. Strategic Recommendations

19. About Us & Disclaimer